Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Bright Minds Biosciences Inc Ordinary Shares C.DRUG

Alternate Symbol(s):  BMBIF

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (CSE:DRUG)

Fundamentals Snapshot (CSE:DRUG)

Opinion & Analysis (CSE:DRUG)

No current opinion is available.

Bullboard Posts (CSE:DRUG)

There’s been a lot of buzz about psychedelic stocks lately

 DRUG has actually kept the gains it made on its mid-August sympathy run.   The psychedelic sector hasn’t caught fire...
OTCLegenda - September 19, 2022

Bright Minds Begins Phase 1 Clinical Trials Focused On Treat

Phase 1 trials are officially underway for Bright Minds Biosciences and their lead product, referred to as BMB-101. The firm this...
AwareInvestor - August 31, 2022

Bright Minds Biosciences Looks To Raise $4.0 Million Via Ove

After several days of intense volatility, Bright Minds Biosciences is looking to capitalize on the sudden investor interest. The firm...
AwareInvestor - August 24, 2022

im in

trying  5k  here   2.17  area   let  her  rip
cueball40 - August 19, 2022

shorts get smoked

they shorted it too low and got greedy, is also short 6,2 million  anson is feeling pain today
hashboy18 - August 18, 2022

Upcoming catalysts

The next couple of catalysts include the toxicology study for 5HT2A to treat MDD/TRD and the Phase-1 clinical trials for BMB-101 to treat...
Whitman19 - April 13, 2022